Epstein-Barr virus Peptide Presented by HLA-E is Predominantly Recognized by CD8bright Cells in multiple Sclerosis Patients

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Jørgensen, Pernille B ^a,c   Livbjerg, Astrid H ^a   Hansen, Hans J ^b   Petersen, Thor ^b   Höllsberg, Per ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; EPSTEIN BARR VIRUS ANTIGEN; HLA A2 ANTIGEN; HLA E ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; TETRAMER;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FOLDING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION;

ADULT; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84866688151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046120     Document Type: Article

References (51)

1. Lassmann H, Bruck W, Lucchinetti CF, (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218.
2. Haahr S, Hollsberg P, (2006) Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 16: 297-310.
3. Ascherio A, Munger KL, (2007) Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61: 288-299.
4. Pender MP, (2009) Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 8: 563-568.
5. Sumaya CV, Myers LW, Ellison GW, (1980) Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 37: 94-96.
6. Sumaya CV, Myers LW, Ellison GW, Ench Y, (1985) Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 17: 371-377.
7. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD, (1983) Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 40: 406-408.
8. Larsen PD, Bloomer LC, Bray PF, (1985) Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 35: 435-438.
9. Munch M, Riisom K, Christensen T, Moller-Larsen A, Haahr S, (1998) The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 97: 171-174.
10. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B, (2004) Epstein-Barr virus in pediatric multiple sclerosis. JAMA 291: 1875-1879.
11. Pohl D, Krone B, Rostasy K, Kahler E, Brunner E, et al. (2006) High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67: 2063-2065.
12. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, et al. (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6: 773-781.
13. Haahr S, Koch-Henriksen N, Moller-Larsen A, Eriksen LS, Andersen HM, (1995) Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1: 73-77.
14. Nielsen TR, Rostgaard K, Nielsen NM, Koch-Henriksen N, Haahr S, et al. (2007) Multiple sclerosis after infectious mononucleosis. Arch Neurol 64: 72-75.
15. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, et al. (2005) Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293: 2496-2500.
16. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, et al. (2007) Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204: 2899-2912.
17. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, et al. (2009) Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132: 3318-3328.
18. Aloisi F, Serafini B, Magliozzi R, Howell OW, Reynolds R, (2010) Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 133: e157.
19. Ransohoff RM, (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622-2629.
20. Barun B, Bar-Or A, (2012) Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 142: 31-37.
21. Jiang H, Canfield SM, Gallagher MP, Jiang HH, Jiang Y, et al. (2010) HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 120: 3641-3650.
22. Jiang H, Wu Y, Liang B, Zheng Z, Tang G, et al. (2005) An affinity/avidity model of peripheral T cell regulation. J Clin Invest 115: 302-312.
23. Rodgers JR, Cook RG, (2005) MHC class Ib molecules bridge innate and acquired immunity. Nat Rev Immunol 5: 459-471.
24. Romagnani C, Pietra G, Falco M, Mazzarino P, Moretta L, et al. (2004) HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Hum Immunol 65: 437-445.
25. Davies A, Kalb S, Liang B, Aldrich CJ, Lemonnier FA, et al. (2003) A peptide from heat shock protein 60 is the dominant peptide bound to Qa-1 in the absence of the MHC class Ia leader sequence peptide Qdm. J Immunol 170: 5027-5033.
26. Imani F, Soloski MJ, (1991) Heat shock proteins can regulate expression of the Tla region-encoded class Ib molecule Qa-1. Proc Natl Acad Sci U S A 88: 10475-10479.
27. Lo WF, Woods AS, DeCloux A, Cotter RJ, Metcalf ES, et al. (2000) Molecular mimicry mediated by MHC class Ib molecules after infection with gram-negative pathogens. Nat Med 6: 215-218.
28. Jiang H, Ware R, Stall A, Flaherty L, Chess L, et al. (1995) Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TCR: a role of the Qa-1 molecule. Immunity 2: 185-194.
29. Panoutsakopoulou V, Huster KM, McCarty N, Feinberg E, Wang R, et al. (2004) Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest 113: 1218-1224.
30. Jiang H, Braunstein NS, Yu B, Winchester R, Chess L, (2001) CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc Natl Acad Sci U S A 98: 6301-6306.
31. Kumar V, (2004) Homeostatic control of immunity by TCR peptide-specific Tregs. J Clin Invest 114: 1222-1226.
32. Li J, Goldstein I, Glickman-Nir E, Jiang H, Chess L, (2001) Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 167: 3800-3808.
33. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, et al. (2004) Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 5: 516-523.
34. Correale J, Villa A, (2008) Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol 195: 121-134.
35. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, et al. (2006) Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 176: 7119-7129.
36. Hollsberg P, Ausubel LJ, Hafler DA, (1994) Human T cell lymphotropic virus type I-induced T cell activation. Resistance to TGF-beta 1-induced suppression. J Immunol 153: 566-573.
37. Weiss EH, Cannich A, Sprinks M, Fernandez N, Ulbrecht M, (1998) Unique biochemical properties of human leukocyte antigen-E allow for a highly specific function in immune recognition. Am J Reprod Immunol 40: 177-182.
38. Watanabe N, De Rosa SC, Cmelak A, Hoppe R, Herzenberg LA, et al. (1997) Long-term depletion of naive T cells in patients treated for Hodgkin's disease. Blood 90: 3662-3672.
39. Ascherio A, Munger KL, (2010) Epstein-barr virus infection and multiple sclerosis: a review. J Neuroimmun Pharmacol 5: 271-277.
40. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, et al. (2010) Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 69: 677-693.
41. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL, (1999) Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 18: 4250-4260.
42. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, et al. (2002) A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 196: 1403-1414.
43. Pietra G, Romagnani C, Falco M, Vitale M, Castriconi R, et al. (2001) The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition. Eur J Immunol 31: 3687-3693.
44. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, et al. (2002) HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 196: 1473-1481.
45. Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, et al. (2010) Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS pathogens 6: e1000782.
46. Jensen PE, Sullivan BA, Reed-Loisel LM, Weber DA, (2004) Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity. Immunol Res 29: 81-92.
47. Ulbrecht M, Modrow S, Srivastava R, Peterson PA, Weiss EH, (1998) Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol 160: 4375-4385.
48. Garcia P, Llano M, de Heredia AB, Willberg CB, Caparros E, et al. (2002) Human T cell receptor-mediated recognition of HLA-E. Eur J Immunol 32: 936-944.
49. Ulbrecht M, Honka T, Person S, Johnson JP, Weiss EH, (1992) The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol 149: 2945-2953.
50. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, et al. (1986) Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans. J Immunol 136: 3636-3642.
51. Kikuta H, Mizuno F, Yano S, Osato T, (1984) Interferon production by Epstein-Barr virus in human mononuclear leukocytes. J Gen Virol 65: 837-841.